SP101, a novel synthetic compound reduces the drug resistance of EGFR(T790M) and cancerous stemness in non-small cell lung carcinoma
| dc.citation.issue | 1 | en_US |
| dc.citation.volume | 30 | en_US |
| dc.contributor.author | Chao, Jui-I | en_US |
| dc.contributor.department | 生物科技學系 | zh_TW |
| dc.contributor.department | 分子醫學與生物工程研究所 | zh_TW |
| dc.contributor.department | Department of Biological Science and Technology | en_US |
| dc.contributor.department | Institute of Molecular Medicine and Bioengineering | en_US |
| dc.date.accessioned | 2018-08-21T05:54:21Z | |
| dc.date.available | 2018-08-21T05:54:21Z | |
| dc.date.issued | 2016-04-01 | en_US |
| dc.identifier.issn | 0892-6638 | en_US |
| dc.identifier.journal | FASEB JOURNAL | en_US |
| dc.identifier.uri | https://ir.lib.nycu.edu.tw/handle/11536/145847 | |
| dc.identifier.wosnumber | WOS:000406444004424 | en_US |
| dc.language.iso | en_US | en_US |
| dc.title | SP101, a novel synthetic compound reduces the drug resistance of EGFR(T790M) and cancerous stemness in non-small cell lung carcinoma | en_US |
| dc.type | Article | en_US |
Files
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed to upon submission
- Description: